Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children10110.24287/1726-1708-2015-14-2-38-42ЛИМФОМЫBrentuximab vedotin in therapy of a patient with refractory Hodgkin’s lymphoma and Proteus syndromeБрентуксимаб ведотин в лечении пациентки с рефрактерной лимфомой Ходжкина и синдромом ПротеяMyakovaN. V.МяковаНаталья Валерьевна
Russian Federation
nmiakova@mail.ruSmirnovaN. V.СмирноваНадежда Владимировна
Russian Federation
nadin-dok@mail.ruEvstratovD. A.ЕвстратовДмитрий Андреевич
Russian Federation
saifpunk@mail.ruAbugovaYu. G.АбуговаЮлия Георгиевна
Russian Federation
abugova_y@mail.ruBalashovD. N.БалашовДмитрий Николаевич
Russian Federation
bala8@yandex.ruDyakonovaYu. Yu.ДьяконоваЮлия Юрьевна
Russian Federation
diakonova80@mail.ruKonovalovD. M.КоноваловДмитрий Михайлович
Russian Federation
dmk_nadf@mail.ruPotapenkoL. A.ПотапенкоЛюдмила Арнельевна
Russian Federation
potapenko-l@mail.ruSkvortsovaYu. V.СкворцоваЮлия Валериевна
Russian Federation
yuscvo@mail.ruMaschanA. A.МасчанАлексей Александрович
Russian Federation
amaschan@mail.ruФедеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева19052015142384219092018Copyright ©; 2015, «D. Rogachev NMRCPHOI»Copyright ©; 2015, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2015«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/101

Despite the generally favorable prognosis, therapy of patients with refractory Hodgkin's lymphoma remains a great problem today. A clinical case is presented: continuously relapsing Hodgkin's lymphoma in a patient (female) with Proteus syndrome. The patient received several lines of chemotherapy and autologous and then haploidentical hematopoietic stem cell transplantation. In addition to the rare combination of Proteus syndrome and Hodgkin's lymphoma, this case is interesting as it presents brentuximab vedotin as effective third-line therapy.

Несмотря на хороший прогноз в целом, лечение пациентов с рефрактерным течением лимфомы Ходжкина остается большой проблемой в настоящее время. Мы описали клинический случай непрерывно-рецидивирующей лимфомы Ходжкина у пациентки с синдромом Протея. Пациентка получила несколько линий химиотерапии и аутологичную, а затем гаплоидентичную трансплантацию гемопоэтических стволовых клеток. Кроме редкого сочетания синдрома Протея и лимфомы Ходжкина, интерес представляет успешное применение у данной пациентки брентуксимаба ведотина в качестве терапии 3-й линии.

лимфома Ходжкинасиндром Протеярефрактерность к терапиибрентуксимаб ведотинHodgkin’s lymphomaProteus syndromedrug resistancebrentuximab vedotinMauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010;28(23):3680-6.Schellong G, Dörffel W, Claviez A, Körholz D, Mann G, Scheel-Walter HG, et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol. 2005;23(25):6181-9.Isidori A, Piccaluga PP, Loscocco F, Guiducci B, Barulli S, Ricciardi T, et al. Highdose therapy followed by stem cell transplantation in Hodgkin's lymphoma: past and future. Expert Rev Hematol. 2013;6(4):451-64.Cole PD, Schwartz CL, Drachtman RA, deAlarcon PA, Chen L, Trippett TM. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report. J Clin Oncol. 2009;27(9):1456-61.Ghesquières H, Stamatoullas A, Casasnovas O, Morschhauser F, Gyan E, Gabarre J, et al. Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients. Leuk Lymphoma. 2013;54(11):2399-404.Moskowitz AJ, Hamlin PA Jr, Perales MA, Gerecitano J, Horwitz SM, Matasar MJ, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013;31(4):456-60.Cohen MM Jr, Hayden PW. A newly recognized hamartomatous syndrome. Birth Defects Orig Artic Ser. 1979;15(5B):291-6.Wiedemann HR, Burgio GR, Aldenhoff P, Kunze J, Kaufmann HJ, Schirg E. The Proteus syndrome. Partial gigantism of the hands and/or feet, nevi, hemihypertrophy, subcutaneous tumors, macrocephaly or other skull anomalies and possible accelerated growth and visceral affections. Eur J Pediatr. 1983; 140(1 ):5-12.Angurana SK, Angurana RS, Panigrahi I, Marwaha RK. Proteus syndrome: clinical profile of six patients and review of literature. Indian J Hum Genet. 2013; 19(2):202-6.Cohen MM Jr. Proteus syndrome review: molecular, clinical, and pathologic features. Clin Genet. 2014;85(2):111-9.Lindhurst MJ, Wang JA, Bloomhardt HM, Witkowski AM, Singh LN, Bick DP, et al. AKT1 gene mutation levels are correlated with the type of dermatologic lesions in patients with Proteus syndrome. J Invest Dermatol. 2014;134(2):543-6.Connors J. Hodgkin's lymphoma. In: Goldman L, Schafer AI, eds. Goldman's Cecil Medicine. 24th ed. Philadelphia, Pa: Elsevier Saunders; 2011:ch.192,1228-33.Hematology. In: Bope ET, Kellerman RD, eds. Conn’s Current Therapy 2014. Philadelphia, Pa: Elsevier Saunders; 2014;Sect.12:820-4.Batlevi CL, Younes A. Novel therapy for Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2013;2013:394-9.von Tresckow B, Engert A. Refractory Hodgkin lymphoma. Curr Opin Oncol. 2013;25(5):463-9.Zinzani PL, Viviani S, Anastasia A, Vitolo U, Luminari S, Zaja F, et al. Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica. 2013;98(8):1232-6.Newland AM, Li JX, Wasco LE, Aziz MT, Lowe DK. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate. Pharmacotherapy. 2013;33(1 ) :93-104.Gibb A, Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica. 2013;98(4):611-4.Iqbal N, Kumar L, Iqbal N. Update on salvage options in relapsed/refractory Hodgkin lymphoma after autotransplant. ISRN Oncol. 2014;2014:605691.Illidge T, Bouabdallah R, Chen R, Gopal AK, Moskowitz CH, Ramchandren R, et al. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma. 2015;56(3):703-10.Mark À, Hajdu M, Varadi Z, Sticz TB, Nagy N, Csomor J, et al. Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study. BMC Cancer. 2013;13:250.